Venetoclax shows potential for R/R hairy cell leukemia

Published Date: 13 Mar 2023

Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

2.

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

3.

Patients face high out-of-pocket costs after incident cancer diagnosis

4.

Childhood cancer survivors face new health problems later in life, study shows

5.

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot